Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

SeaStar Medical Holding (ICUCW) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for SeaStar Medical Holding (ICUCW) over the last 3 years, with Q3 2025 value amounting to -$3.5 million.

  • SeaStar Medical Holding's Income towards Parent Company rose 2246.54% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.7 million, marking a year-over-year increase of 5424.87%. This contributed to the annual value of -$24.8 million for FY2024, which is 534.46% up from last year.
  • As of Q3 2025, SeaStar Medical Holding's Income towards Parent Company stood at -$3.5 million, which was up 2246.54% from -$2.0 million recorded in Q2 2025.
  • Over the past 5 years, SeaStar Medical Holding's Income towards Parent Company peaked at -$2.0 million during Q2 2025, and registered a low of -$12.7 million during Q1 2024.
  • For the 3-year period, SeaStar Medical Holding's Income towards Parent Company averaged around -$5.5 million, with its median value being -$4.4 million (2024).
  • As far as peak fluctuations go, SeaStar Medical Holding's Income towards Parent Company plummeted by 7893.18% in 2024, and later surged by 7029.22% in 2025.
  • SeaStar Medical Holding's Income towards Parent Company (Quarter) stood at -$9.5 million in 2023, then skyrocketed by 53.27% to -$4.4 million in 2024, then grew by 21.43% to -$3.5 million in 2025.
  • Its Income towards Parent Company stands at -$3.5 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$3.8 million for Q1 2025.